Background: Few studies suggest that the combined increase in plasma triglycerides (TG) and in waist circumference (WC), termed 'hypertriglyceridemic waist' (HTGW), is an interesting marker of risk for cardiovascular disease (CVD). Objective: Using cutoffs used for defining HTGW, we examined the prospective association of HTGW with CVD risk in a French cohort of men. Design: Men were participants in the SU.VI.MAX study, an intervention trial testing the impact of an antioxidant supplementation on chronic diseases. Data were collected in 1994-1996 in 3430 men followed up for 7.5 years. Cutoffs used for defining HTGW were WC X90 cm and TG X2 mmol/l. We assessed the relative risk (RR) (95% confidence interval (CI)) of CVD in groups defined according to both WC and TG levels. Results: In this population, 41.2% of the subjects were classified as low WC/low TG, 43.2% as high WC/low TG, 3.5% as low WC/high TG and 12.1% as HTGW. During follow-up, 122 subjects had a CVD event. In this group, HTGW prevalence was 26.2%. After adjustment for age, RR (95% CI) for CVD for the HTGW group showed the highest association with CVD risk: 2.13 (1.21-3.76), using low WC/ low TG as the reference group. Conclusion: HTGW was associated with the risk of CVD after 7.5 years of follow-up in a low-risk middle-aged men population. This marker may be used as a useful clinical tool to screen for men at risk of CVD.
Introduction
Obesity is known to be associated with increased cardiovascular morbidity and mortality. 1, 2 Independently of overall adiposity, as defined by body mass index (BMI, kg/m 2 ), abdominal fat accumulation assessed with anthropometric indicators such as waist-hip ratio, sagittal diameter, or more simply waist circumference (WC), increases the risk for cardiovascular disease (CVD). [3] [4] [5] [6] [7] There is general agreement that increased intra-abdominal (or visceral) fat is particularly deleterious in relation with CVD risk, 8 and WC is one of the anthropometric indicators strongly correlated with this fat depot. 9 Consensus conferences have defined WC cutoffs for increased risk in women and men, respectively. 1 Mechanisms for increased CVD risk with increasing abdominal fat include the close associations of abdominal fat with metabolic CVD risk factors such as increased triglycerides (TG), as part of the insulin resistance or metabolic syndrome. 1 Some recent prospective studies have also shown that increased TG level may be an independent CVD risk factor in European [10] [11] [12] and US populations. 13 In recent years, Després et al. 15 coined the term 'hypertriglyceridemic waist' (HTGW) to emphasize the potential predictive value of the combined increase in WC and TG in relation with CVD risk. 14, 15 These authors showed that men with HTGW were at increased risk for coronary artery disease (CAD) and suggested that the HTGW phenotype could represent a simple and inexpensive tool to screen for high-risk subjects. 14, 16 Similar findings were reported in a few other cross-sectional studies. 17, 18 Evidence of the relationship between HTGW with CVD risk in prospective studies is scarce. To our knowledge, there is only one recent study that found, in postmenopausal women followed up for 8.5 years, that HTGW was associated with a 4.7-fold increased risk for fatal CVD events. 19 The French population is characterized by a rather low rate of CVD morbidity and mortality and a lower prevalence of abdominal obesity compared to the situation currently prevailing in Northern America. 20, 21 To assess the utility of the HTGW phenotype as atherogenic marker in such a population, we investigated the relationship of baseline HTGW status with CVD risk after 7.5 years of follow-up in middle-aged French men included in the SU.VI.MAX ('SUpplémentation en VItamines et Minéraux Anti-oXydants') Study.
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Methods
Study subjects
Subjects were participants in the SU. VI.MAX study, a randomized double-blind placebo-controlled primaryprevention trial designed to test the impact of a daily antioxidant supplementation at nutritional doses on the incidence of cancers and ischemic CVDs. 22, 23 In total, 13 017 subjects from all over France were included in 1994-1995 and were followed up for 7.5 years. All subjects gave their informed written consent to the study, which was approved by a local ethical committee and the national committee for the protection of privacy and civil liberties. We excluded subjects with CVD before enrollment and during the first year of follow-up (n ¼ 29) and those with missing data on biological, clinical or other covariates of interest. On the 8423 remaining subjects, we also excluded women from the analyses (n ¼ 4993), because of the few number of incident CVD events that occurred during follow-up (n ¼ 29). Thus, 3430 men were included for the present analysis. Diabetic subjects were included in the analyses.
Clinical examination and laboratory methods BMI was measured after 1 year of follow-up and overweight or obesity was defined as a BMI X25 kg/m 2 . WC was measured as the circumference midway between lower ribs and iliac crests in subjects in a standing position. During the same year, blood pressure (BP) was measured at each arm using a standard mercury sphygmomanometer in subjects who had been lying down for 10 min. If systolic blood pressure (SBP) was 4160 mm Hg or diastolic blood pressure (DBP) 490 mm Hg then readings were taken again after a second rest period of 5 min and the lowest value was kept. 22 Blood samples were obtained at baseline after a 12-h fast, and all biochemical measurements were centralized. Serum total cholesterol and TG levels were measured by an enzymatic method (Bayer Diagnostics, NY, USA), apolipoprotein-A1 (apo-A1) and apolipoprotein-B (apo-B) by immunonephelemetry (Behring, Deerfield, IL, USA) and fasting glucose by a glucose-oxidase method (Bayer Diagnostics). 22 High-density lipoprotein cholesterol (HDL-c) was calculated using the measured value of apo-A1, derived from an equation developed in the AMORIS Study. 24 Smoking status (current versus never or previous smokers) was obtained from a questionnaire at baseline, as was the habitual level of physical activity (summary of transportation, work, leisure) that was coded into three categories: inactivity, o1 h/day of physical activity or X1 h/day.
Subjects were divided into four groups according to WC (o90 or X90 cm) and TG levels (o2 mmol/l or X2 mmol/l): low WC/low TG, high WC/low TG, low WC/high TG and high WC/high TG ('HTWG').
CVD assessment and follow-up During follow-up, participants were asked to complete a monthly health-related questionnaire via mail, internet or Minitel Telematic Network (a terminal widely used in France in 1994-1995, as an adjunct to the telephone). Once a possible event was suspected, all relevant records, including results of diagnostic tests and procedures were collected from the physicians and hospitals involved or directly from participants. Incident CVD outcomes included the following: new-onset angina (n ¼ 41), fatal and non-fatal myocardial infarction or stroke (n ¼ 62), transient ischemic attack (n ¼ 1), sudden death (n ¼ 6) or intermittent claudication (n ¼ 12) (ICD codes I20-I25, I63, I65, I66, I70, I71 and I74). All data were reviewed by an expert committee, who was blinded for supplementation assignment. CVD was confirmed by radiologist reports or by a combination of clinical, biological and electrocardiographic criteria, as appropriate. Causes of death were confirmed by information from relatives or physicians. At the end of the follow-up period (1 September 2002), vital status of all subjects and causes of death were verified using the national death registry.
Statistical analysis
Pearson w 2 and Student's unpaired t-tests, where appropriate, were used to compare baseline variables between groups (CVD cases versus non-cases and subjects with HTGW versus those without it). Cox proportional hazards regression models were used to assess the effect associated with a 1 s.d. increase in each risk factor in relation with CVD risk. Analyses were age-adjusted. Relative risks (RRs) and 95% confidence intervals (CIs) are presented. We also used Cox models for modeling the associations between groups defined based on WC and TG cutoffs with incident CVD. The group defined by both low WC and low TG level (HTGW) was considered as the reference group with a CVD RR of 1.0 assigned for comparisons. Both age-adjusted and multivariate-adjusted models (age, current smoking, physical activity, SBP, DBP and fasting glucose) are presented. All analyses were performed with SAS 8.2 (SAS Institute Inc., Hypertriglyceridemic waist and CVD risk in men S Czernichow et al Cary, NC, USA). All reported P-values are two-sided tests and Po0.05 was considered statistically significant.
Results
Population characteristics
Among the 3430 men included in the analysis, 122 CVD events occurred during follow-up. At baseline, 41.2% of subjects from the total sample were classified as low WC/low TG, 43.2% as high WC/low TG, 3.5% as low WC/high TG and 12.1% as HTGW. Table 1 compares baseline characteristics of subjects who did and those who did not develop a CVD event during the 7.5 years of follow-up. Levels of CVD risk factors were all significantly (Po0.001) higher in CVD cases compared to non-cases, except for physical activity. Percentage of overweight or obese subjects (BMI X25 kg/m 2 ) at baseline was significantly higher in CVD cases than in non-cases (71.3 versus 52.2%, Po0.0001), as was the frequency of the HTGW phenotype (26.2 versus 12.1%, Po0.001).
Compared to subjects without HTGW those with HTGW had significantly higher mean baseline levels for conventional risk factors, lower mean apo-A1 level, were more frequently smokers and physically inactive ( Table 2) . Percentage of overweight or obese subjects (BMIX25 kg/m 2 ) at baseline was markedly higher in subjects with HTGW than in those without HTGW (86.8 versus 48.2%, Po0.0001). Percentage of diabetic subjects (fasting plasma glucoseX 7 mmol/l or antidiabetic treatment use) was higher in those with HTGW than in those without HTGW (20.6 versus 5.2%, Po0.0001).
Age-adjusted analysis of cardiovascular risk factors and CVD risk Age-adjusted RRs (95% CI) for CVD, according to 1 s.d. increase in each CVD risk factor, are presented in Table 3 . Total cholesterol, apo-B, apo-B/A1, SBP, DBP, fasting plasma glucose and BMI were associated with an increased risk of CVD. Apo A1 and HDL-c were inversely associated with this risk.
WC, TG levels and CVD risk Figure 1 presents multivariate-adjusted (age, smoking status, overall physical activity level, SBP, DBP and fasting blood glucose) RRs of CVD events, according to groups defined according to baseline WC and TG levels. Using low WC/low TG as the reference category, RR (95% CI) for CVD was: 0.72 
Discussion
Results of this study, in a cohort of middle-aged French men, document a 2.13-fold increase in CVD risk after 7.5 years of follow-up in subjects characterized by enlarged WC and elevated TG. These data give strong support to the contention that the HTGW phenotype might be considered as a simple but useful predictive marker of CVD in middle-aged men.
Previous evidence on the association of HTGW with CVD comes mainly from cross-sectional studies. 16, 18, 25 In a seminal study by Lemieux et al. 14 (n ¼ 287 men), HTGW was predictive of angiographically assessed CAD with an odds ratio (OR) of 3.6 (1.2-10.9) compared to the low WC/ low TG group as reference. In another study by the same authors, the cross-sectional relationships of the HTGW phenotype with CAD were analyzed according to fasting glucose level. 16 The OR for the HTGW group, as compared to low WC/low TG group, was 8.5 (3.5-20.4) in subjects with raised fasting glucose (6.1-6.9 mmol/l) and 5.4 (3.1-9.3) in those with normal glucose level (o6.1 mmol/l). 16 Other risk factors were, however, not taken into account. In a crosssectional analysis in Turkish men, HTGW was also predictive of age-adjusted fatal and non-fatal CAD risk. 18 In a subsample of the Cross-Cultural Activity Participation Study (CAPS), a trend for higher 10-year Framingham risk score was observed among HTGW women, compared to those classified as non-HTGW. 26 However, the Framingham risk score may not always capture the risk associated with an atherogenic profile if subjects with HTGW do not have deleterious traditional risk factor levels. 26 To date, only one prospective study has addressed the utility of HTGW in estimating CVD risk. In 557 postmenopausal Danish women followed up for 8.5 years, Tanko et al. 19 recently reported that HTGW (WCX88 cm and TGX1.45 mmol/l) was associated with an increased risk for fatal cardiovascular events (RR: 4.7, 2.2-9.8), after adjustment for age, smoking and low-density lipoprotein (LDL) cholesterol. Together with these findings, our data in a larger sample of men, strengthen the interest of the HTGW concept in relation with occurrence of CVD. It extends previous research by showing that it applies even in populations with a rather low prevalence of obesity, such as found in France. 2 Indeed, the overall prevalence of the HTGW phenotype in our subjects was 11.6 or 22.6% in those with CVD, compared to 11% (5-16%) in a study in US women, 26 19% in men from the Quebec Health Survey 25 and approximately 35% in men from the NAHNES III survey, with the same age range. 17 CVD remains, however, the leading cause of death in France emphasizing the need for efficient but practical risk markers at individual and population level. 27 In our study, total cholesterol, apo-B, -A1, apo-B/A1 ratio but also TG were predictive of CVD risk during follow-up. Several recent studies have described the predictive effect of TG and apo-A1 and -B.
10,21,24,28 After 10 years of follow-up in the Hoorn study, the age-and sex-adjusted RR for CVD was 1.35 (1.11-1.64) for baseline TG. 10 Previously, in the Copenhagen Male Study, it was shown that a high TG level was a strong predictor of ischemic heart disease after an 8-year follow-up, independently of other major risk factors. 28 In our study, we measured apo-A1 and not HDL-c. However, apo-A1 is highly correlated to HDL-c and was even a stronger predictor of coronary heart disease than HDL-c in men from the Prospective Epidemiological Study of Myocardial classified on WC and fasting TG levels (low TG and low WC as the reference group) (adjusted for age, active smoking, physical activity, SBP, DBP and fasting blood glucose). Similar results were observed in the prospective AMORIS Study, with fatal myocardial infarction as outcome. 24 As shown by our data, men characterized by the HTGW phenotype displayed increased levels of all other major cardiovascular risk factors including BP, total cholesterol, apo-A1/B, smoking and physical inactivity ( Table 2) . As expected, a great majority of these subjects were also classified as overweight or obese. This is in line with findings from Kahn and Valdez 17 who illustrated the utility of HTGW to identify subjects with atherogenic 'lipid overaccumulation' associated with insulin resistance. In a cross-sectional analysis of data from the NHANES III survey, these authors showed HTGW to be associated with increased apo-B, decreased HDL-c, increased fasting glucose, fasting insulin and homeostasis model assessment index for insulin resistance. 17 Investigators in Quebec had found previously that WC was best correlated with fasting insulin, insulin resistance and apo-B level, whereas TG was correlated to the highly atherogenic small, dense LDL particles. 9, 14, 30, 31 Therefore, HTGW would first stand as a surrogate marker for a particularly deleterious dyslipidemic, insulin-resistant and pro-inflammatory profile, associated with abdominal obesity. Interestingly, in the present study, HTGW remained significantly associated with the risk of CVD events after adjustment for BP, fasting glucose, smoking and physical activity in addition to age. WC, shown to be closely correlated with intra-abdominal (visceral) fat, 9 is an anthropometric measure easily obtained in primary care settings. 32 A widely accepted concept is that both anatomical and metabolic properties of intraabdominal fat explain the relationships of this specific fat depot with atherosclerosis. Visceral adipocytes are known to have a high lipolytic activity resulting in an increased free fatty acids (FFA) release in the portal vein. This will lead to impairments in glucose uptake and oxidation by muscles and other organs and also lead to accumulation of FFA in the liver, pancreas and muscles contributing to insulin resistance. Increased FFA also provide substrate for liver TG-rich lipoprotein production. 33 A potential limitation may be highlighted in our study: TG were measured at baseline, whereas WC was measured 1 year after. During this first year, 29 CVD events occurred. It may be hypothesized that the characteristics of these subjects may be different compared to those with a CVD event occurring after this first year of follow-up. In order to prevent any bias, we have excluded these 29 subjects from the analyses. Comparison of the characteristics of these excluded subjects with those included in the present analysis (n ¼ 122 CVD events) did not show any significant difference for age, BMI, WC, TG, fasting blood glucose, BP or physical activity level (data not shown).
In conclusion, in this prospective cohort study in middleaged men, the HTGW phenotype was a strong predictive marker of CVD risk. These results give further support to the notion that HTGW represents a simple clinical tool to screen men at increased risk for CVD.
